Amicus Therapeutics Hits New 52-Week High at $14.50

Amicus Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.50 on April 24, 2026. This achievement marks a notable increase from its 52-week low of USD 5.51, reflecting a substantial upward trend in the stock's performance over the past year. With a market capitalization of USD 4,512 million, Amicus Therapeutics continues to navigate the competitive landscape of the biotechnology industry. The company currently operates without a dividend yield, and its price-to-book ratio stands at 19.58, indicating a premium valuation relative to its book value. Additionally, the company's debt-to-equity ratio is 0.59, suggesting a moderate level of leverage. Despite facing challenges in profitability, as indicated by a negative return on equity of -5.36%, the recent price movement highlights a shift in market dynamics for Amicus Therapeutics. Investors and market observers will be keen to monitor how this momentum influences the company's future trajectory within the biotechnology sector.